Whole-exome sequencing reveals changes in the ATO-resistant cell lines at the genomic level. (A) The Cancer Genome Atlas (TCGA) AML data set was compared with novel mutations observed in NB4EV-AsR1 and UF1 cell lines; the graph represents the novel mutations (found only in resistant cell lines) and their mutation frequency. (B) Sanger sequencing showing the existence of PML^A216V in the in-house–generated ATO-resistant cell line but not in the UF1 and parental NB4 naïve cell line. (C) Mutations observed in the p53 gene of ATO-resistant and sensitive cell lines.